vs
Side-by-side financial comparison of Grupo Aeromexico, S.A.B. de C.V. (AERO) and Organon & Co. (OGN). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $1.4B, roughly 1.0× Grupo Aeromexico, S.A.B. de C.V.). Grupo Aeromexico, S.A.B. de C.V. runs the higher net margin — 11.5% vs 10.0%, a 1.5% gap on every dollar of revenue.
Grupo Aeromexico is Mexico's flagship airline holding company, offering domestic and international passenger and cargo air transport services. It operates a wide route network covering North America, South America, Europe and Asia, serving leisure and business travel segments with a modern commercial aircraft fleet.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
AERO vs OGN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $1.5B |
| Net Profit | $165.0M | $146.0M |
| Gross Margin | — | 53.6% |
| Operating Margin | 21.1% | — |
| Net Margin | 11.5% | 10.0% |
| Revenue YoY | — | -3.5% |
| Net Profit YoY | — | 67.8% |
| EPS (diluted) | — | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.5B | ||
| Q4 25 | $1.4B | $1.5B | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | — | $1.6B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | — | $1.6B |
| Q1 26 | — | $146.0M | ||
| Q4 25 | $165.0M | $-205.0M | ||
| Q3 25 | — | $160.0M | ||
| Q2 25 | — | $145.0M | ||
| Q1 25 | — | $87.0M | ||
| Q4 24 | — | $109.0M | ||
| Q3 24 | — | $359.0M | ||
| Q2 24 | — | $195.0M |
| Q1 26 | — | 53.6% | ||
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 54.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.4% |
| Q1 26 | — | — | ||
| Q4 25 | 21.1% | -9.8% | ||
| Q3 25 | — | 15.2% | ||
| Q2 25 | — | 14.4% | ||
| Q1 25 | — | 6.7% | ||
| Q4 24 | — | 8.1% | ||
| Q3 24 | — | 13.1% | ||
| Q2 24 | — | 14.6% |
| Q1 26 | — | 10.0% | ||
| Q4 25 | 11.5% | -13.6% | ||
| Q3 25 | — | 10.0% | ||
| Q2 25 | — | 9.1% | ||
| Q1 25 | — | 5.8% | ||
| Q4 24 | — | 6.8% | ||
| Q3 24 | — | 22.7% | ||
| Q2 24 | — | 12.1% |
| Q1 26 | — | $0.55 | ||
| Q4 25 | — | $-0.78 | ||
| Q3 25 | — | $0.61 | ||
| Q2 25 | — | $0.56 | ||
| Q1 25 | — | $0.33 | ||
| Q4 24 | — | $0.42 | ||
| Q3 24 | — | $1.38 | ||
| Q2 24 | — | $0.75 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AERO
| Passenger | $1.3B | 91% |
| Air Cargo | $82.0M | 6% |
| Other | $52.0M | 4% |
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
